LOW-DOSE PHOSPHODIESTERASE III INHIBITOR (CILOSTAZOL) REDUCES THE VASCULAR AMYLOID BURDEN IN AMYLOID-Β PROTEIN PRECURSOR TRANSGENIC MICE

2017 ◽  
Author(s):  
Yusuke Yakushiji
Keyword(s):  
Transgenic Mice ◽  
Low Dose ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Amyloid Burden ◽  
Protein Precursor ◽  
Β Protein ◽  
Phosphodiesterase Iii Inhibitor ◽  
Phosphodiesterase Iii

Transcranial Laser Therapy Attenuates Amyloid-β Peptide Neuropathology in Amyloid-β Protein Precursor Transgenic Mice

2011 ◽  
Vol 23 (3) ◽  
pp. 521-535 ◽  
Author(s):  
Luis De Taboada ◽  
Jin Yu ◽  
Salim El-Amouri ◽  
Sebastiano Gattoni-Celli ◽  
Steve Richieri ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Laser Therapy ◽  
Amyloid Β ◽  
Amyloid Β Peptide ◽  
Amyloid Β Protein ◽  
Protein Precursor ◽  
Β Protein

Impaired neurotransmitter systems by Aβ amyloidosis in APPsw transgenic mice overexpressing amyloid β protein precursor

2000 ◽  
Vol 292 (3) ◽  
pp. 155-158 ◽  
Author(s):  
Yasushi Tomidokoro ◽  
Yasuo Harigaya ◽  
Etsuro Matsubara ◽  
Masaki Ikeda ◽  
Takeshi Kawarabayashi ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Protein Precursor ◽  
Neurotransmitter Systems ◽  
Β Protein

Neurodegeneration and Gliosis in Transgenic Mice Overexpressing a Carboxy-Terminal Fragment of Alzheimer Amyloid-β Protein Precursor

1997 ◽  
Vol 8 (5) ◽  
pp. 296-307 ◽  
Author(s):  
Masahiro Sato ◽  
Takeshi Kawarabayashi ◽  
Mikio Shoji ◽  
Takashi Kobayashi ◽  
Norihiro Tada ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Amyloid Β ◽  
Amyloid Β Protein ◽  
Protein Precursor ◽  
Terminal Fragment ◽  
Β Protein ◽  
Carboxy Terminal

scholarly journals Low-Dose Phosphodiesterase III Inhibitor Reduces the Vascular Amyloid Burden in Amyloid-β Protein Precursor Transgenic Mice

2020 ◽  
Vol 21 (7) ◽  
pp. 2295 ◽  
Author(s):  
Yusuke Yakushiji ◽  
Kazuhiro Kawamoto ◽  
Kazuyoshi Uchihashi ◽  
Masafumi Ihara ◽  
Shigehisa Aoki ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Senile Plaque ◽  
Amyloid Β ◽  
Control Group ◽  
Amyloid Angiopathy ◽  
Amyloid Β Protein ◽  
Amyloid Burden ◽  
Phosphodiesterase Iii Inhibitor ◽  
The Brain ◽  
Aspirin Group

A previous study reported that relatively high-dose cilostazol (0.3%) promoted the drainage of cerebrovascular amyloid-β (Aβ) protein in Aβ Precursor Protein (APP) transgenic mice overexpressing vasculotropic Aβ. We investigated whether lower-dose cilostazol can decrease micro-hemorrhages and Aβ deposition in the brain using APP transgenic mice. At baseline, 14-month-old female Tg2576 mice were randomly assigned to a control group (vehicle), aspirin group (0.01% aspirin), or cilostazol group (0.01% cilostazol). The severity of cerebral micro-hemorrhages (i.e., number), area of senile plaque, and severity of vascular amyloid burden (quantified with cerebral amyloid angiopathy (CAA) score (=number of Aβ-positive vessels × severity of amyloid burden of Aβ-positive vessels) were evaluated in the brain of mice aged 15 and 21–23 months. At 15 months, no differences were shown in each pathological change among the three groups. At 21–23 months, there were no differences in the severity of cerebral micro-hemorrhages or area of senile plaque among the three groups. However, the CAA score was significantly lower in the cilostazol compared to the control group (p = 0.046, Mann–Whitney U test), although no difference was seen between the control and aspirin group. Our study showed that lower-dose cilostazol could reduce the vascular amyloid burden without increasing cerebral micro-hemorrhages in APP transgenic mice.

Sign in / Sign up

Export Citation Format

Share Document